Waters Corporation (NYSE: WAT) reported today third quarter 2012 sales of $450 million, a 1% decrease in comparison to sales of $455 million in the third quarter of 2011. For the quarter, foreign currency translation reduced sales growth by 3%. On a GAAP basis, earnings per diluted share (E.P.S.) for the third quarter were $1.12 compared to $1.10 for the third quarter in 2011. On a non-GAAP basis, E.P.S. were up 4% to $1.18 in the third quarter of 2012 from $1.14 in the third quarter of 2011. A reconciliation of GAAP to non-GAAP E.P.S. is attached.
Through the first nine months of 2012, sales for the Company were $1,322 million, a decline of 1% in comparison to sales of $1,330 million in the first nine months of 2011. Foreign currency translation reduced sales growth during the first nine months of 2012 by 3%. E.P.S. for the first nine months of 2012 were $3.19 compared to $3.18 for the comparable period in 2011. On a non-GAAP basis and including adjustments on the attached reconciliation, E.P.S. grew 3% in the first nine months of 2012 to $3.35 from $3.26 in 2011.
Commenting on the quarter, Douglas Berthiaume, Chairman, President and Chief Executive Officer said, “Stable pharmaceutical demand and strong sales in Asia allowed us to organically grow our revenue in the third quarter despite challenging market conditions. At the same time, tight expense control, disciplined product pricing and a continuation of our share repurchase program resulted in adjusted earnings per share growth at a rate faster than sales.”
As communicated in a prior press release, Waters Corporation will webcast its third quarter 2012 financial results conference call this morning, October 23, 2012 at 8:30 a.m. eastern time. To listen to the call, connect to www.waters.com, choose “Investor” and click on the Live Webcast. A replay of the call will be available through October 30, 2012, similarly by webcast and also by phone at 402-220-4610.About Waters Corporation: For over 50 years, Waters Corporation (NYSE: WAT) has created business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide. Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV